BRIEF-Sangamo's genome editing program to transfer to Biogen's spin-off Bioverativ By: Reuters: Company News November 30, 2016 at 07:23 AM EST * Sangamo's genome editing program for hemoglobinopathies to transfer to biogen's spin-off bioverativ Read More >> Related Stocks: Sangamo Therapeutics